David E. Olson

Employment

• University of California Davis Professor
  2024 - Present
• University of California, Davis Professor
  2024 - Present
• University of California, Davis Director
  2022 - Present
• Delix Therapeutics Chief Innovation Officer and Head of Scientific Advisory Board
  2021 - Present
• University of California, Davis Affiliate Member
  2021 - Present
• University of California, Davis Associate Professor
  2021 - 2024
• University of California, Davis Associate Professor
  2021 - 2024
• Delix Therapeutics Co-Founder, President, and Chief Scientific Officer
  2019 - 2021
• University of California, Davis Affiliate Member
  2015 - Present
• University of California, Davis Assistant Professor
  2015 - 2021
• University of California, Davis Assistant Professor
  2015 - 2021

Education

• Broad Institute of MIT and Harvard Postdoctoral Associate
  ? - 2015
• Stanford University Ph.D.
  ? - 2011
• Union College B.S.
  ? - 2006

Projects & Funding

Projects & funding information is unavailable.

Publications (77)

• Synthesis of Clausenamide Isomers and Evaluation of Their Potential as Cortical Neuroplastogens
  ACS Chemical Neuroscience 2026 DOI: 10.1021/acschemneuro.5c00767
  +Save
• R-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential
  ACS Chemical Neuroscience 2026 DOI: 10.1021/acschemneuro.5c00891
  +Save
• Skeletal editing by iron-catalyzed carbene insertion of trichloromethanes
  Chem 2026 DOI: 10.1016/j.chempr.2026.102968
  +Save
• Toward Translatable Biomarkers of Psychedelic-Induced Neuroplasticity
  AMERICAN JOURNAL OF PSYCHIATRY 2025 DOI: 10.1176/APPI.AJP.20231054
  +Save
• The psychoplastogen tabernanthalog induces neuroplasticity without proximate immediate early gene activation
  NATURE NEUROSCIENCE 2025 DOI: 10.1038/S41593-025-02021-1
  +Save
• Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring
  NATURE COMMUNICATIONS 2025 DOI: 10.1038/S41467-025-64371-5
  +Save
• Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential
  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2025 DOI: 10.1073/PNAS.2416106122
  +Save
• Ketamine induces plasticity in a norepinephrine-astroglial circuit to promote behavioral perseverance
  NEURON 2025 DOI: 10.1016/J.NEURON.2024.11.011
  +Save
• Indolethylamine N-Methyltransferase Deletion Impacts Mouse Behavior without Disrupting Endogenous Psychedelic Tryptamine Production
  ACS CHEMICAL NEUROSCIENCE 2025 DOI: 10.1021/ACSCHEMNEURO.5C00384
  +Save
• Efficient and modular synthesis of ibogaine and related alkaloids
  Nature Chemistry 2025 DOI: 10.1038/s41557-024-01714-7
  +Save